Nomacopan is under clinical development by Akari Therapeutics and currently in Phase III for Thrombotic Microangiopathy. According to GlobalData, Phase III drugs for Thrombotic Microangiopathy does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Nomacopan LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nomacopan is under development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), uveitis, atopic keratoconjunctivitis (AKC), Guillain-Barre syndrome (GBS), pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), COVID-19 pneumonia, trauma, dry age-related macular degeneration (dry-AMD), dry eye and haemorrhagic shock, antiphospholipid syndrome and myasthenia gravis (MG) and lung disease, severe asthma and chronic obstructive pulmonary disease. The therapeutic candidate is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick. It is administered through subcutaneous, intravitreal and ophthalmic routes. It is also administered through inhalational route as nebulized form. It acts by targeting complement C5 and leukotriene B4 (LTB4). It was also under development for the treatment of bullous pemphigoid (BP), benign mucous membrane pemphigoid, Sjogren's syndrome and atypical hemolytic uremic syndrome (aHUS).
Akari Therapeutics overview
Akari Therapeutics (Akari), formerly Celsus Therapeutics, is a biopharmaceutical company. The company is engaged in the development of therapeutic treatments for rare and orphan autoimmune and inflammatory diseases. It offers coversin drugs that act on complement component-C5 that helps in preventing the release of C5a and formation of C5b – 9. Akari’s pipeline products include paroxysmal nocturnal hemoglobinuria, Guillain Barre Syndrome and atypical hemolytic uremic syndrome. The pipeline products include LTB4+C5, Coversin, Coversin LA, LTB4, LTBA LA, and bioamine inhibitors. It operates its business in Switzerland, Israel, the UK and the US. Akari is headquartered in London, Greater London, the UK.
For a complete picture of Nomacopan’s drug-specific PTSR and LoA scores, buy the report here.